Improving Blood and Marrow Transplants for Older Adults

BMT Core - Johns Hopkins

NIH-funded research Johns Hopkins University · NIH-11164551

This program aims to make blood and marrow transplantation safer and more effective, especially for older patients with blood cancers.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-11164551 on NIH RePORTER

What this research studies

This program at Johns Hopkins focuses on making blood and marrow transplantation (BMT) better for patients. A key success has been developing a method called post-transplant cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD), which allows more people to receive life-saving transplants, even with mismatched donors. The team is now working to improve BMT outcomes specifically for older patients, as traditional risk assessments don't work as well for them. They are looking into new ways to reduce transplant-related side effects in this age group, with a particular focus on those over 70.

Who could benefit from this research

Good fit: Patients who are 65 or older and need a blood and marrow transplant for a hematologic malignancy might be ideal candidates for future related studies.

Not a fit: Patients who do not require a blood and marrow transplant or are not in the older age group may not directly benefit from this specific focus.

Why it matters

Potential benefit: If successful, this work could make blood and marrow transplantation safer and more widely available, especially for older patients with blood cancers.

How similar studies have performed: The development of post-transplant cyclophosphamide (PTCy) has already been established as a new standard of care in a large, multi-institutional trial, demonstrating success with this approach.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.